PMV Pharmaceuticals, Inc.
Datakwaliteit: 83%
PMVP
NASDAQ
Manufacturing
Chemicals
€ 1,42
▼
€ 0,05
(-3,40%)
6 months return
—
Momentum
Neutral
ROE
-59,43%
Groei
Revenue Growth (5Y)
N/A
Revenue (1Y)N/A
Earnings (1Y)N/A
FCF Growth (3Y)N/A
Kwaliteit
Return on Equity
-59,43%
Onder sectorgemiddelde (-54,47%)
ROIC-51,83%
Net MarginN/A
Op. MarginN/A
Veiligheid
Debt / Equity
N/A
Current Ratio10,76
Interest Coverage-13,60
Waardering
PE (TTM|NTM)
-0,91 | -1,20
Boven sectorgemiddelde (-1,50)
P/B Ratio0,58
EV/EBITDAN/A
Dividend YieldN/A
Quick Summary
Key Takeaways
Short bullets derived from reported financials—not the AI summary above.
Negative free cash flow of -73,61 M
Price History
Financiële Trends
Koersdoel Analisten
4 analisten
Buy
+234.5%
upside to target
Huidig
€ 1,42
Consensus Target
€ 4,75
€ 4,00
Laag
€ 6,00
Hoog
Vooruitzicht
Forward K/W
-1,20
Forward WPA
-€ 1,10
Omzet Sch.
2,97 M
Winstverassingen
EPS
Reported
Estimate
Forecast
Next: Q1 2026
·
EPS Est: -€ 0,39
·
Rev Est: 0,0
| Q12025 | Q22025 | Q32025 | Q42025 | Q1 '26 | Q2 '26 | |
|---|---|---|---|---|---|---|
| Reported | -€ 0,34 | -€ 0,41 | -€ 0,40 | -€ 0,34 | — | — |
| Estimate | -€ 0,38 | -€ 0,39 | -€ 0,40 | -€ 0,40 | -€ 0,39 | -€ 0,42 |
| Verrassing | +11,30% | -6,49% | +0,62% | +13,92% | — | — |
Growth
Rev 5Y: N/A · Earnings 1Y: N/A
Growth
Rev 5Y: N/A · Earnings 1Y: N/A| Revenue Growth (1Y) | N/A | Revenue Growth (3Y) | N/A |
| Earnings Growth (1Y) | N/A | Earnings Growth (3Y) | N/A |
| Revenue Growth (5Y) | N/A | Earnings Growth (5Y) | N/A |
Profitability
ROE: -59,43% · Net Margin: N/A
Profitability
ROE: -59,43% · Net Margin: N/A| Revenue (TTM) | N/A | Net Income (TTM) | -77,74 M |
| ROE | -59,43% | ROA | -54,23% |
| Gross Margin | N/A | Operating Margin | N/A |
| Net Margin | N/A | Free Cash Flow (TTM) | -73,61 M |
| ROIC | -51,83% | FCF Growth (3Y) | N/A |
Safety
D/E: N/A · Current: 10,76
Safety
D/E: N/A · Current: 10,76| Debt / Equity | N/A | Current Ratio | 10,76 |
| Interest Coverage | -13,60 | Asset Turnover | N/A |
| Working Capital | 120,15 M | Tangible Book Value | 121,00 M |
Dividends
Yield: N/A · Payout: N/A
Dividends
Yield: N/A · Payout: N/A| Dividend Yield | N/A | Payout Ratio | N/A |
| Dividend Growth (3Y) | N/A | Dividend Growth (5Y) | N/A |
| Consecutive Div Years | N/A | ||
Valuation
P/E: -0,91 · EV/EBITDA: N/A
Valuation
P/E: -0,91 · EV/EBITDA: N/A| P/E Ratio | -0,91 | Forward P/E | -1,20 |
| P/B Ratio | 0,58 | P/S Ratio | N/A |
| PEG Ratio | N/A | Forward PEG | N/A |
| EV/EBITDA | N/A | Fwd EV/EBITDA | N/A |
| Forward P/S | 23,77 | Fwd Earnings Yield | N/A |
| FCF Yield | -104,17% | ||
| Market Cap | 70,66 M | Enterprise Value | 34,32 M |
Per Share
EPS: -1,48 · FCF/Share: -1,38
Per Share
EPS: -1,48 · FCF/Share: -1,38| EPS (Diluted TTM) | -1,48 | Revenue / Share | N/A |
| FCF / Share | -1,38 | OCF / Share | -1,38 |
| EPS CAGR (1Y) | N/A | EPS CAGR (5Y) | N/A |
| EPS CAGR (10Y) | N/A | ||
Efficiency
FCF Conv: 94,68% · CapEx/Rev: N/A
Efficiency
FCF Conv: 94,68% · CapEx/Rev: N/A| CapEx / Revenue | N/A | FCF Conversion | 94,68% |
| SBC-Adj. FCF | -80,78 M | Growth Momentum | N/A |
Income Statement
Annual, most recent first
Income Statement
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | — | — | — | — | — |
| Net Income | -77,74 M | -58,71 M | -68,96 M | -73,32 M | -57,85 M |
| EPS (Diluted) | -1,48 | -1,14 | -1,44 | -1,61 | — |
| Gross Profit | — | — | — | — | — |
| Operating Income | -86,21 M | -85,45 M | -80,13 M | -77,04 M | -58,29 M |
| EBITDA | — | — | — | — | — |
| R&D Expenses | 69,88 M | 58,53 M | 55,89 M | 51,99 M | 36,49 M |
| SG&A Expenses | — | — | — | — | — |
| D&A | — | — | — | — | — |
| Interest Expense | 6,34 M | 10,66 M | 11,17 M | 3,63 M | 449.000,0 |
| Income Tax | -2,17 M | -16,10 M | 2.000,0 | -9.000,0 | 23.000,0 |
Balance Sheet
Annual, most recent first
Balance Sheet
Annual, most recent first| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Total Assets | 116,56 M | 191,29 M | 252,15 M | 270,31 M | 331,57 M |
| Total Liabilities | 11,85 M | 15,21 M | 26,46 M | 24,28 M | 23,01 M |
| Shareholders' Equity | 104,71 M | 176,08 M | 225,69 M | 246,03 M | 308,56 M |
| Total Debt | — | — | — | — | — |
| Cash & Equivalents | 37,98 M | 40,88 M | 37,71 M | 108,30 M | 172,47 M |
| Current Assets | 115,23 M | 175,66 M | 207,41 M | 247,01 M | 301,29 M |
| Current Liabilities | 11,42 M | 14,37 M | 14,03 M | 10,83 M | 12,22 M |
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers)
Vergeleken met vergelijkbare bedrijven in Manufacturing
Sectorvergelijking
vs Manufacturing sector mediaan (1605 peers) Vergeleken met vergelijkbare bedrijven in Manufacturing| Metriek | Aandeel | Sector Mediaan |
|---|---|---|
| P/E | -0,9 | -1,5 |
| P/B | 0,6 | 1,6 |
| ROE % | -59,4 | -54,5 |
| Net Margin % | — | -41,5 |
| Rev Growth 5Y % | — | 1,7 |
| D/E | — | 0,3 |
{"event":"ticker_viewed","properties":{"ticker":"PMVP","listing_kind":"stock","pathname":"/stocks/pmvp","exchange":"NASDAQ","country":"US"}}